NANETS 2014 Symposium

Pancreatic Cancer: An Exocrine and Endocrine Disease

NANETS 2014 Symposium

Tumor-Specific Mutations More Common in High-Grade Neuroendocrine Tumors

By

Bryant Furlow

October 10, 2014

Tumor-specific mutations are common in high-grade neuroendocrine tumors.

Novel Therapy May Be Effective for Neuroendocrine Tumors

NANETS 2014 Symposium

Gene Panel Identifies Primary Tumor Sites in Metastatic Neuroendocrine Tumors

By

Bryant Furlow

October 10, 2014

A 3-marker immunohistochemistry panel helps determine the primary site of malignancy in metastatic neuroendocrine tumors.

Next post in NANETS 2014 Symposium

$Everolimus Use in Sorafenib-Refractory Hepatocellular Carcinoma$

NANETS: Despite Dose Reductions, Everolimus Promising in Advanced Pancreatic Neuroendocrine Tumors